Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

GlobeNewswire

October 03, 2024



The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024The collaboration supports Teva's Pivot to Growth strategy and adds to the company’s biosimilar portfolio Both companies reaffirm their shared commitment to making high-quality, affordable treatments accessible to patients worldwide

Related

---